Liquidia Corporation

NasdaqCM:LQDA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 1.13 B

Share Price

USD 13.26

Avg Daily Volume

1,539,774

Change (1 day)

0.68%

Change (1 year)

8.69%

Change (YTD)

12.75%

Liquidia Corporation Total Assets for the year ending December 31, 2024: USD 230.31 M

Liquidia Corporation Total Assets is USD 230.31 M for the year ending December 31, 2024, a 94.63% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Liquidia Corporation Total Assets for the year ending December 31, 2023 was USD 118.33 M, a -8.41% change year over year.
Liquidia Corporation Total Assets for the year ending December 31, 2022 was USD 129.20 M, a 37.84% change year over year.
Liquidia Corporation Total Assets for the year ending December 31, 2021 was USD 93.73 M, a -5.83% change year over year.
Liquidia Corporation Total Assets for the year ending December 31, 2020 was USD 99.53 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Assets	Accounts Payable	Short-Term Debt	Long-Term Debt

NasdaqCM: LQDA

Liquidia Corporation

CEO	Dr. Roger A. Jeffs Ph.D.
IPO Date	July 26, 2018
Location	United States
Headquarters	419 Davis Drive
Employees	170
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.